Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
On Monday, the House passed a bipartisan bill designed to reportedly boost scientific research and increase the scientific competitiveness of the U.S. to that of China.
Major players in the biotech industry are targeting Ohio for their new facilities, including Amgen, which recently dropped $365 million on a “digitally advanced” smart facility just 15 miles outside the state’s capital.
Three partnerships were signed today between biopharmaceutical and therapeutics companies in a bid to develop treatment for major diseases with high mortality rates.
Rinvoq shows promising results for Ulcerative Colitis Treatment. The company said more patients treated with Rinvoq in the 52-week study achieved clinical remission compared to placebo.
The deal was originally inked in 2005, where U.S.-based Chiron Corp. made payments to Genentech, a Roche company.
Here’s a look at some of the top COVID-19-related stories for today.
Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.
A new study published in Nature offers good news for those who recovered from COVID-19 and were then vaccinated with a mRNA vaccine – a booster may not be needed.
If approved, lenacapavir would be offered to HIV patients who have been heavily treated for the disease and have multi-drug-resistant HIV.
The groundbreaking success of the mRNA vaccines for COVID-19 by Pfizer-BioNTech and Moderna has led the way for other companies with a vested interest in vaccine development.
The two companies studying the regimen for HCC, Exelixis and Ipsen, suggest the probability of reaching significance at the final analysis is low.
Tofersen is the furthest along of four ASOs currently in clinical development for ALS and as such, there is quite a bit riding on the results of the VALOR trial which has an estimated completion date of August 31st, 2021.